MERS-CoV Nucleocapsid Antibody

Catalog #: MAB10729 Datasheet / COA / SDS

Catalog #	Availability	Size / Price	Qty
MAB10729-100
MAB10729-SP

Detection of MERS-CoV MERS-CoV Nucleocapsid by Western Blot.

2 Images

All Nucleocapsid Antibodies

Product Details

Supplemental Products

Reviews

Summary Data Examples Preparation and Storage Reconstitution Calculator Background Product Datasheets Related Research Areas

MERS-CoV Nucleocapsid Antibody Summary

Species Reactivity

MERS-CoV

Specificity

Detects Mouse MERS-CoV Nucleocapsid in direct ELISAs.

Source

Monoclonal Mouse IgG_2B Clone # 1038729

Purification

Protein A or G purified from hybridoma culture supernatant

Immunogen

Spodoptera frugiperda insect ovarian cell line Sf21-derived mouse MERS-CoV Nucleocapsid
Met1-Thr411
Accession # YP_007188586.1

Formulation

Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.

Label

Unconjugated

Applications

Recommended Concentration

Sample

Western Blot

1 µg/mL

Recombinant MERS-CoV Nucleocapsid protein

Simple Western

25 µg/mL

Recombinant MERS-CoV nucleocapsid

Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.

Scientific Data

Western Blot

View Larger

Detection of MERS-CoV MERS-CoV Nucleocapsid by Western Blot. Western blot shows recombinant MERS-CoV Nucleocapsid protein. PVDF membrane was probed with 1 µg/mL of Mouse Anti-Mouse MERS-CoV Nucleocapsid Monoclonal Antibody (Catalog # MAB10729) followed by HRP-conjugated Anti-Mouse IgG Secondary Antibody (HAF018). A specific band was detected for MERS-CoV Nucleocapsid at approximately 49 kDa (as indicated). This experiment was conducted under reducing conditions and using Western Blot Buffer Group 1.

Simple Western

View Larger

Detection of Nucleocapsid by Simple Western^TM. Simple Western lane view shows recombinant MERS-CoV nucleocapsid, loaded at 0.2 mg/mL. A specific band was detected for Nucleocapsid at approximately 57 kDa (as indicated) using 25 µg/mL of Mouse Anti-MERS-CoV Nucleocapsid Monoclonal Antibody (Catalog # MAB10729). This experiment was conducted under reducing conditions and using the 12-230 kDa separation system.

Reconstitution Calculator

Preparation and Storage

Reconstitution

Reconstitute at 0.5 mg/mL in sterile PBS.

Shipping

Lyophilized product is shipped at ambient temperature. Liquid small pack size (-SP) is shipped with polar packs. Upon receipt, store immediately at the temperature recommended below.

Stability & Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

12 months from date of receipt, -20 to -70 °C as supplied.
1 month, 2 to 8 °C under sterile conditions after reconstitution.
6 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: Nucleocapsid

MERS-CoV, which causes the Middles East Respiratory Syndrome (MERS), belongs to a family of viruses known as coronaviruses that are commonly comprised of four structural proteins: Spike protein (S), Envelope protein (E), Membrane protein (M), and Nucleocapsid protein (N) (1). While the S, E and M proteins build up the viral envelope, the N protein is involved transcription, replication and packaging of the viral RNA genome into a helical ribonucleocapsid (RNP) (1, 2). The MERS-CoV N protein is a ~45 kDa protein composed of two independent structural domains connected by a linker region. The N-terminal region contains an Intrinsically Disordered Region (3) and an RNA binding domain (4), the linker region interacts with the M protein and the C-terminal region contains a self-association domain (1, 2). The MERS-CoV N protein shares 46.3% and 4.5% amino acid sequence identity with SARS-CoV-1 and SARS-CoV-2 N protein, respectively. MERS-CoV N proteins have been shown to inhibit Type I Interferon(IFN) production(1). In addition, the N protein is an abundant protein during coronavirus infection and displays high immunogenic activity, making it a promising therapeutic target (5-7).

References